Outcome of patients with newly diagnosed AML admitted to the ICU, including preemptive admission - a multi-center study.
Acute myeloid leukemia
Early pre-emptive admission
Hyperleukocytosis
Induction chemotherapy
Intensive care unit
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
25
10
2022
accepted:
29
03
2023
medline:
15
5
2023
pubmed:
12
4
2023
entrez:
11
4
2023
Statut:
ppublish
Résumé
Acute myeloid leukemia (AML) can lead to life-threatening complications that may require intensive care unit (ICU) management. It has been advocated that early preemptive (ePE) ICU admission, before the onset of organ failure, could benefit some high-risk patients such as those with hyperleukocytosis. The aim of this study was to retrospectively analyze the outcome of newly diagnosed AML patients who required ICU admission in five academic centers with a special focus on patients with an ePE admission strategy, i.e., those transferred to the ICU without any organ failure (modified SOFA score ≤ 2 [omitting thrombocytopenia] and no life-sustaining intervention in the first 24 h following ICU admission) before the start of induction therapy. Between January 2017 and December 2019, 428 patients were included among which 101 were admitted to the ICU. Among patients requiring life-sustaining interventions (n = 83), 18 (22%) died while in the ICU but ICU survivors had the same survival as those not admitted to the ICU. Patients with an ePE admission (n = 18) had more comorbidities and high-risk disease features such as hyperleukocytosis but required no life-sustaining interventions while in the ICU. In a subgroup analysis of patients with hyperleukocytosis ≥ 50 G/l at diagnosis (n = 85), patients not admitted to the ICU and those admitted with an ePE strategy had similar outcomes. This study provides encouraging results about ICU outcome in AML patients during induction therapy but the potential benefit of an ePE strategy must be confirmed prospectively.
Identifiants
pubmed: 37039874
doi: 10.1007/s00277-023-05205-6
pii: 10.1007/s00277-023-05205-6
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1383-1393Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Shah A, Andersson TM-L, Rachet B et al (2013) Survival and cure of acute myeloid leukaemia in England, 1971–2006: a population-based study. Br J Haematol 162:509–516. https://doi.org/10.1111/bjh.12425
doi: 10.1111/bjh.12425
pubmed: 23786647
Juliusson G, Lazarevic V, Hörstedt A-S et al (2012) Acute myeloid leukemia in the real world: why population-based registries are needed. Blood 119:3890–3899. https://doi.org/10.1182/blood-2011-12-379008
doi: 10.1182/blood-2011-12-379008
pubmed: 22383796
pmcid: 3358248
Halpern AB, Culakova E, Walter RB, Lyman GH (2017) Association of risk factors, mortality, and care costs of adults with acute myeloid leukemia with admission to the intensive care unit. JAMA Oncol 3:374. https://doi.org/10.1001/jamaoncol.2016.4858
doi: 10.1001/jamaoncol.2016.4858
pubmed: 27832254
pmcid: 5344736
Jackson K, Mollee P, Morris K et al (2014) Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unit. Leuk Lymphoma 55:97–104. https://doi.org/10.3109/10428194.2013.796045
doi: 10.3109/10428194.2013.796045
pubmed: 23597137
Maeng CV, Østgård LSG, Christiansen CF, Liu KD (2021) Changes in intensive care unit admission rates, organ support, and mortality in patients with acute myeloid leukaemia over a 12-year period: a Danish nationwide cohort study. Br J Haematol 195:137–140. https://doi.org/10.1111/bjh.17630
doi: 10.1111/bjh.17630
pubmed: 34101163
pmcid: 8478792
Maeng CV, Christiansen CF, Liu KD et al (2022) Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort study. Leuk Lymphoma 63:2290–2300. https://doi.org/10.1080/10428194.2022.2074984
Schellongowski P, Staudinger T, Kundi M et al (2011) Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience. Haematologica 96:231–237. https://doi.org/10.3324/haematol.2010.031583
doi: 10.3324/haematol.2010.031583
pubmed: 21071501
Azoulay E, Mokart D, Pène F et al (2013) Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium–a groupe de recherche respiratoire en réanimation onco-hématologique study. J Clin Oncol Off J Am Soc Clin Oncol 31:2810–2818. https://doi.org/10.1200/JCO.2012.47.2365
doi: 10.1200/JCO.2012.47.2365
Darmon M, Thiery G, Ciroldi M et al (2005) Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy. Crit Care Med 33:2488–2493
doi: 10.1097/01.CCM.0000181728.13354.0A
pubmed: 16276171
Fassbind P, Jeker B, Mueller BU et al (2019) Improved survival rates of AML patients following admission to the intensive care unit. Leuk Lymphoma 60:2423–2431. https://doi.org/10.1080/10428194.2019.1594213
Ahmed T, Koch AL, Isom S et al (2017) Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit. Leuk Res 62:51–55. https://doi.org/10.1016/j.leukres.2017.09.017
doi: 10.1016/j.leukres.2017.09.017
pubmed: 28985622
pmcid: 5682208
Atallah E, Cortes J, O’Brien S et al (2007) Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood 110:3547–3551. https://doi.org/10.1182/blood-2007-06-095844
doi: 10.1182/blood-2007-06-095844
pubmed: 17673605
Ferreyro BL, Scales DC, Wunsch H et al (2021) Critical illness in patients with hematologic malignancy: a population-based cohort study. Intensive Care Med 47:1104–1114. https://doi.org/10.1007/s00134-021-06502-2
doi: 10.1007/s00134-021-06502-2
pubmed: 34519845
Thiéry G, Azoulay É, Darmon M et al (2005) Outcome of Cancer Patients Considered for Intensive Care Unit Admission: A Hospital-Wide Prospective Study. J Clin Oncol 23:4406–4413. https://doi.org/10.1200/JCO.2005.01.487
doi: 10.1200/JCO.2005.01.487
pubmed: 15994150
Lengliné E, Raffoux E, Lemiale V et al (2012) Intensive care unit management of patients with newly diagnosed acute myeloid leukemia with no organ failure. Leuk Lymphoma 53:1352–1359. https://doi.org/10.3109/10428194.2011.649752
doi: 10.3109/10428194.2011.649752
pubmed: 22233111
Saillard C, Elkaim E, Rey J et al (2018) Early preemptive ICU admission for newly diagnosed high-risk acute myeloid leukemia patients. Leuk Res 68:29–31. https://doi.org/10.1016/j.leukres.2018.02.015
doi: 10.1016/j.leukres.2018.02.015
pubmed: 29522988
Mottal N, Issa N, Dumas P-Y et al (2020) Reduce mortality and morbidity in acute myeloid leukemia with hyperleukocytosis with early admission in intensive care unit: a retrospective analysis. J Hematol 9:109–115. https://doi.org/10.14740/jh691
Pigneux A, Harousseau J-L, Witz F et al (2010) Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS. J Clin Oncol Off J Am Soc Clin Oncol 28:3028–3034. https://doi.org/10.1200/JCO.2009.26.4648
doi: 10.1200/JCO.2009.26.4648
Lancet JE, Uy GL, Cortes JE et al (2018) CPX-351 (cytarabine and daunorubicin) Liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol 36:2684–2692. https://doi.org/10.1200/JCO.2017.77.6112
doi: 10.1200/JCO.2017.77.6112
Grimwade D, Hills RK, Moorman AV et al (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116:354–365. https://doi.org/10.1182/blood-2009-11-254441
doi: 10.1182/blood-2009-11-254441
pubmed: 20385793
Döhner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424–447. https://doi.org/10.1182/blood-2016-08-733196
doi: 10.1182/blood-2016-08-733196
pubmed: 27895058
pmcid: 5291965
Savic A, Kvrgic V, Rajic N et al (2012) The hematopoietic cell transplantation comorbidity index is a predictor of early death and survival in adult acute myeloid leukemia patients. Leuk Res 36:479–482. https://doi.org/10.1016/j.leukres.2011.11.021
doi: 10.1016/j.leukres.2011.11.021
pubmed: 22192632
Sorror ML, Storer BE, Fathi AT et al (2017) Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality. JAMA Oncol 3:1675. https://doi.org/10.1001/jamaoncol.2017.2714
doi: 10.1001/jamaoncol.2017.2714
pubmed: 28880971
pmcid: 5824273
Palmieri R, Othus M, Halpern AB et al (2020) Accuracy of SIE/SIES/GITMO consensus criteria for unfitness to predict early mortality after intensive chemotherapy in adults with AML or other high-grade myeloid neoplasm. J Clin Oncol 38:4163–4174. https://doi.org/10.1200/JCO.20.01392
doi: 10.1200/JCO.20.01392
pubmed: 33030979
pmcid: 8462659
Walter RB, Othus M, Borthakur G et al (2011) Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol 29:4417–4424. https://doi.org/10.1200/JCO.2011.35.7525
doi: 10.1200/JCO.2011.35.7525
pubmed: 21969499
pmcid: 3221524
Sasaki K, Kadia T, Begna K et al (2022) Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol 97:68–78. https://doi.org/10.1002/ajh.26395
doi: 10.1002/ajh.26395
pubmed: 34716921
Le Gall JR, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–2963. https://doi.org/10.1001/jama.270.24.2957
doi: 10.1001/jama.270.24.2957
pubmed: 8254858
Vincent JL, de Mendonça A, Cantraine F et al (1998) Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med 26:1793–1800. https://doi.org/10.1097/00003246-199811000-00016
doi: 10.1097/00003246-199811000-00016
pubmed: 9824069
Rabbat A, Chaoui D, Montani D et al (2005) Prognosis of patients with acute myeloid leukaemia admitted to intensive care. Br J Haematol 129:350–357. https://doi.org/10.1111/j.1365-2141.2005.05459.x
doi: 10.1111/j.1365-2141.2005.05459.x
pubmed: 15842658
Roze des Ordons AL, Chan K, Mirza I et al (2010) Clinical characteristics and outcomes of patients with acute myelogenous leukemia admitted to intensive care: a case-control study. BMC Cancer 10:516. https://doi.org/10.1186/1471-2407-10-516
Azoulay E, Pochard F, Kentish-Barnes N et al (2005) Risk of post-traumatic stress symptoms in family members of intensive care unit patients. Am J Respir Crit Care Med 171:987–994. https://doi.org/10.1164/rccm.200409-1295OC
doi: 10.1164/rccm.200409-1295OC
pubmed: 15665319